Cost–effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain

Aim: To estimate the cost–effectiveness of treating postmenopausal osteoporosis (PMO) with weekly gastro-resistant risedronate 35 mg gastro-resistant tablets (RIS-GR), compared with weekly alendronate 70 mg tablets (ALN) in Spain. Methods: A probabilistic analysis (second-orderMonte Carlo simulati...

Полное описание

Библиографические подробности

Главные авторы:	Enrique Casado, Jose Rosas, Carlos Rubio-Terres, Dario Rubio-Rodriguez, Mitra Boolell, Ignacio Aristegui
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Becaris Publishing Limited 2023-09-01
Серии:	Journal of Comparative Effectiveness Research
Предметы:	alendronate cost–effectiveness postmenipausal osteoporosis risedronate gastro-resistant
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!